Raquel F. Reinoso
Research Subjects
Raquel F. Reinoso has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Albert Dordal
WELAB, Parc Científic Barcelona C/Baldiri Reixac 4–8 08028 Barcelona Spain
1 shared publication - Anita Wegert
Symeres Kerkenbos 1013 6546 BB Nijmegen, The Netherlands
1 shared publication Antoni Torrens
WELAB, Parc Científic Barcelona C/Baldiri Reixac 4–8 08028 Barcelona Spain
1 shared publication- Carmen Almansa
ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
1 shared publication - Enrique Portillo-Salido
WeLab Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Spain
1 shared publication Frank van Holst
Symeres Kerkenbos 1013 6546 BB Nijmegen, The Netherlands
1 shared publication
Latest Publications
- 17 January 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (10) , e202300473
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ‐1 subunit of voltage‐gated calcium channels (Cavα2δ‐1) and the μ‐opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ‐1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino‐acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug‐drug interactions. A representative compound, (2S,4S)‐4‐(4‐chloro‐3‐(((cis)‐4‐(dimethylamino)‐4‐phenylcyclohexyl)methyl)‐5‐fluorophenoxy)pyrrolidine‐2‐carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side‐effect profile in relation to morphine.
- 17 January 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (10) , e202300473
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ‐1 subunit of voltage‐gated calcium channels (Cavα2δ‐1) and the μ‐opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ‐1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino‐acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug‐drug interactions. A representative compound, (2S,4S)‐4‐(4‐chloro‐3‐(((cis)‐4‐(dimethylamino)‐4‐phenylcyclohexyl)methyl)‐5‐fluorophenoxy)pyrrolidine‐2‐carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side‐effect profile in relation to morphine.